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Abstract (150 words) 
Adult neural stem cells (NSCs) must tightly regulate quiescence and proliferation. Single cell analysis has 
suggested a continuum of cell states as NSCs exit quiescence. Here we capture and characterize in vitro 
primed quiescent NSCs and identify LRIG1 as an important regulator. We show that BMP-4 signaling 
induces a dormant non-cycling quiescent state (d-qNSCs), whereas combined BMP-4/FGF-2 signalling 
induces a distinct primed quiescent state poised for cell cycle re-entry. Primed quiescent NSCs (p-qNSCs) 
are defined by high levels of LRIG1 and CD9, as well as an interferon response signature, and can 
efficiently engraft into the adult subventricular zone (SVZ) niche. Genetic disruption of Lrig1 in vivo within 
the SVZ NSCs leads an enhanced proliferation. Mechanistically, LRIG1 primes quiescent NSCs for cell 
cycle re-entry and EGFR responsiveness by enabling EGFR protein levels to increase but limiting signaling 












Homeostasis in many adult tissues requires the balancing of stem cell proliferation and 
differentiation. Tissue stem cells often reside in a non-cycling quiescent state. Generation of new cells that 
are needed for tissue turnover and repair therefore requires tight regulation as cells transit from dormant 
or slow cycling states, into rapid proliferation. The mechanisms controlling this fundamental process are 
not well understood, but once determined may open up new rational therapeutic strategies to control stem 
cell activity to treat disease or tissue injury 8,49. Understanding regulation of quiescence is also of 
importance in oncology, as quiescent cancer cells evade standard cytotoxic therapies and drive regrowth 
of the tumour. 
 
Neural stem cells (NSCs) are situated within two major neurogenic zones of the adult mouse brain: the 
sub-granular zone of the hippocampus (SGZ)18, and the sub-ventricular zone (SVZ) lining the lateral 
ventricles41. SVZ NSCs are responsible for the production of neuroblasts that migrate along the rostral 
migratory stream (RMS), destined for terminal neuronal differentiation in the olfactory bulb (OB)41. Adult 
NSCs are heterogeneous with regards to cell cycle status and exist in a range of distinct quiescent and 
proliferative states that are poorly understood. Quiescent stem cells are by definition non-cycling and lack 
expression of proliferative markers such as Ki67 and MCM231 .  
 
Quiescent adult NSCs express GFAP and CD133/prominin6,13,14. These cells generate the rapidly 
proliferating amplifying progenitors (type C cells), which are GFAP negative, and express high levels of 
epidermal growth factor receptor (EGFR) and mitotic markers such as MCM245 NSC quiescence is 
controlled in vivo by a complex repertoire of signals provided by the SVZ niche16. These include local cell-
cell interactions, secreted factors from the blood or cerebrospinal fluid, as well as longer range signals from 
neuronal inputs or factors secreted from the choroid plexus35,52,53. These must all be integrated by the NSCs 
to regulate cell behaviour and fate. 
 
A subset of GFAP-expressing NSCs in the SVZ expresses EGFR, and are actively cycling. These have 
been termed activated NSCs45. Indeed, EGF is a key mitogen for NSCs, both in vitro and in vivo1,15,17,25,45. 
Despite the complex array of signals within the NSC niche, candidates for regulating NSC fate have 
emerged, including: BMPs, FGFs and EGF signaling pathways. In the SVZ, BMP-2 and BMP-4 are 
secreted predominantly by neural stem and progenitor cells; Noggin is produced by adjacent ependymal 
cells that line the ventricles24. The BMP downstream effector, Id1 is a marker of quiescent NSCs in vivo37. 
This local niche herefore regulates the cell cycle state1,19,24,46,57. 
 
Single cell RNA-seq analysis has also revealed a continuum of cell states during activation of quiescent 
NSCs and their transition into rapidly proliferative progenitors27. This includes a ‘primed’ quiescent state27. 
However, single cell snapshots of gene expression cannot provide information on cellular dynamics. Also, 
clonal lineage tracing of NSC cell fate in the adult SVZ in vivo is challenging. It has therefore remained 
unclear whether primed GFAP+EGFR+ cells exist transiently, or instead represent a distinct and stable cell 
type. It also is difficult to dissect key biochemical regulatory processes in vivo, as these cell populations 
are rare and located deep in the adult brain. How do activated NSCs emerge from their more dormant 
ancestors? Do they have a unique transcriptional identity and regulatory apparatus? What mechanisms 
control EGFR activation and cell cycle re-entry? 
 
Exposure of proliferating mouse NSCs to BMP-4 causes cells to rapidly exit the cell cycle, downregulate 
NSC markers (e.g. Nestin) and upregulate astrocyte markers such as GFAP10,46, leading to the suggestion 
that BMP triggers terminal astrocyte differentiation. However, in vivo type B quiescent NSCs also express 
GFAP13 and can be low or negative for Nestin9. BMP-induced astrocytic cells may therefore be dormant 
NSCs, rather than terminally differentiated astrocytes as originally thought. Indeed, BMP4 triggers 
quiescence in adult NSCs both in vitro and in vivo3,55,30, but it remains unclear whether this requires co-
stimulation of other pathways such as FGF signalling55 and whether distinct quiescent states are induced. 
 
Here, we therefore explored the differences between NSCs cultured in BMP4 alone and BMP4/FGF2.  We 
hypothesized that a distinct primed quiescent NSC state may be imposed by BMP with FGF-2 combined, 
whereas BMP may induce a deeper quiescent state. We report culture conditions that can capture distinct 
quiescent states. Cross-comparison of these distinct cell states we uncover defining molecular features of 
each. LRIG1, a negative regulator of RTK signaling38, emerges as a critical gatekeeper of the exit from 
quiescence. LRIG1 enables increases in EGFR protein, but constrains activation of signaling. Genetic 
ablation of Lrig1 in NSCs in vivo leads an increase of proliferation. In this way the Lrig1-expressing 
quiescent NSCs become primed, and are poised for cell cycle re-entry and subsequent transition into the 
activated and proliferative NSCs.  
Results 
Quiescent neural stem cells in vivo can be subdivided into putative deep and shallow quiescent 
states using a Fucci2a reporter and CD9    
The Fucci system was developed to enable live cell visualisation of cell cycle, as it contains fluorescent 
proteins with cell cycle stage-dependent degrons50. To understand the diversity of quiescent NSC states 
in the adult mouse brain, we first characterized the SVZ of Fucci2a reporter mice36. Improved Fucci2a mice 
were developed by Mort et al., and contain a bicistronic cassette targeted to the Rosa26 safe harbor 
encoding aVenus-hGem and mCherry-hCdt1 linked by a T2A self-cleaving peptide sequence36 . These 
enable monitoring of distinct cell cycle phases: early G1 or G0 (black/low red), late G1 or shallow G0 (high 
red), G1/S (yellow) and S/G2/M phase (green). 
 
Surprisingly, during the characterization of the adult SVZ from Fucci2a reporter mice we uncovered an 
unexpected heterogeneity in the levels of the mCherry-Cdt1 reporter in the GFAP populations (Figure 1a) 
(mCherry-Cdt1high levels: 24.5%; low levels: 57.1%; and negative: 17.3%; n=3). The subset of GFAP-
expressing cells that were brightest for mCHERRY, also co-expressed CD9 (Figure 1b), which 
distinguishes NSCs from parenchymal astrocytes and is a marker of a subset of activated qNSCs (type B 
cells) (Llorens-Bobadilla et al., 2015). CD9 expression was detectable in 82.04±2.3% of the total GFAP 
population. We scored high and low levels of CD9 in the GFAP population and only 20% of the GFAP 
population express high levels of CD9. These highest CD9 expressing cells also co-expressed the highest 
mCherry levels. We analysed the Fucci2a SVZ by immunocytochemistry for the proliferative marker KI67 
and the mCHERRY reporter but could not identify any GFAP+KI67+ cells with high levels of mCherry; from 
the GFAP+Ki67+ population only 10.66±4.04% displayed low levels of mCherry and 89.33±4.04 were 
negative for the red reporter (Figure Supplementary 1a). Cells with highest levels of mCherry were also 
negative for S100B, consistent with a qNSC identity (Figure Supplementary 1b) (Raponi et al., 2007). We 
found ependymal cells lining the ventricle and S100B+ expressed high mCherry. Our results suggest that 
qNSCs in vivo can be subdivided based on the levels of mCherry-Cdt1 Fucci reporter and levels of the 
surface marker CD9 and these might mark distinct G0 or quiescent states. 
 
As our goal was to dissect the regulatory mechanisms that control qNSC exit from quiescence we focussed 
on in vitro analysis, where the biochemical signalling pathways, transcriptional and clonal proliferative 
capacity can be experimentally dissected. We derived proliferative NSC cultures from the Fucci reporter 
mice (expanded in EGF/FGF-2). Fucci NSCs cultures displayed all the key markers (Figure 1e), 
morphology and differentiation capacity as previously reported for adherent NSCs (Figure 1c) 10.  
 
To induce quiescence, we withdrew EGF and exposed cells to either BMP or combined BMP/FGF. In both 
conditions cells exit cycle and acquire astrocytic morphology (Figure 1c).  After 3 days we determined 
reporter levels using flow cytometry (Figure 1d). As expected, under proliferating conditions (EGF/FGF), a 
full range of cell cycle stages was indicated by the Fucci reporter (Figure 1c and 1d). In both BMP and 
BMP/FGF we did not detect any Venus-hGem expressing (S/G2/M) as cells are not cycling (Figure 1d). 
However, there was a significant heterogeneity in the proportions and levels of the mCherry-Cdt1 with 
significantly higher levels in BMP/FGF compared to BMP alone.  Similar to the in vivo situation, the 
mCherry-hCdt1high cells in BMP/FGF co-expressed high levels of CD9 (Figure 1f and 1g) and upon sorting 
and replating into EGF/FGF conditions this double positive subpopulation contained all of the NSC colony-
forming activity (Figure 1h and Supplementary 1c). BMP/FGF culture conditions therefore seem to induce 
a primed qNSC state (p-qNSCs) that is in a shallow quiescence, whereas in BMP alone the cells 
correspond to a more dormant quiescent qNSC state (d-qNSCs). 
 
Proliferative neural stem cells can be directed into distinct quiescent states in vitro 
To extend the findings from the Fucci NSCs we focused on an independent wild-type NSC line derived 
from C57BL6 adult brain, which has no fluorescent reporter transgenes. The BL6-NSCs were karyotypically 
normal4 and expressed standard NSC markers (Figure 2b). Using flow cytometry we found, similarly to the 
Fucci-NSC results, the levels of CD9 protein were highest in BMP/FGF treatment relative to either BMP 
alone or EGF/FGF (proliferating NSCs) (Figure 2a). Moreover, there were similar differential cellular 
phenotypes; the BMP/FGF were clearly more elongated, with more compact and rounded nuclei. SOX2 is 
a key neural stem cell marker, and in BMP/FGF we observed increased protein levels in each cell (similar 
to EGF/FGF) and more homogeneous across the cell population (Figure 2b). We analyzed cell cycle of the 
different conditions using DNA content (Figure 2c) and we didn’t find any significant difference in cell cycle 
between BMP alone and BMP/FGF. 
 
In both BMP and BMP/FGF conditions qNSCs retained expression of markers associated with Notch 
signaling and Shh signaling (Hes5, Gli1, Gli3) as well as Sox9, FoxG1, and Id19,11,28,37,51 (Figure 2e). 
However, in the BMP/FGF condition these were typically higher (Figure 2e). p21 (Cdkn1a) was not 
increased, suggesting these are not driven into senescence (Figure 2e). To assess functional differences 
between the BMP and BMP/FGF-induced states, we tested their ability to re-enter the cell cycle upon return 
to EGF/FGF. Both EdU incorporation (Figure 2f) and NSC colony formation assays indicated that BMP/FGF 
treated cells were more readily able re-enter cell cycle (Figure 2f and 2g).  
 
Fucci reporters cannot distinguish G0 and G1. We therefore next explored the candidate regulator p27 
(encoded by Cdkn2b), which is thought to mark G02,43. BMP cells were found to be very high for p27 protein 
using immunocytochemistry compared to BMP/FGF, and therefore in a deep G0 state (Supplementary 1f 
and 1g). In vitro generated quiescent NSCs are therefore being driven into a p27-expressing G0 state. 
However, the higher p27 levels in BMP alone versus BMP/FGF suggested deeper quiescence, consistent 
with the differential responses to EGF/FGF in our colony formation experiments (Figure 2f). To extend the 
characterization of cell cycle markers, we created a double knock-in mCherry-p27 and eGFP-PCNA 
reporter NSC line. We found that NSCs in EGF/FGF, displayed high levels of PCNA and are negative for 
p27 (Figure 2d and Supplementary 1d-1g). BMP and BMP/FGF treated cells become cell cycle arrested 
and consistently have activated p27 but low PCNA (Figure 2c and Supplementary 1d-1g). However, the 
putative primed NSCs in BMP/FGF have lower p27 levels than in BMP alone, consistent with them being 
in a shallower or primed state (Figure 2d). 
Quiescent NSCs in vivo have previously been shown to have reduced rates of translation24,25. Using O-
propargyl-puromycin (OP-Puro) incorporation assays we confirmed that BMP or BMP/FGF treated cells 
did indeed have reduced levels of translation (Supplementary 2b-2c). Altogether, the above data suggest 
we can model two distinct types of quiescence: p-qNSCs and d-qNSCs. 
 
Primed quiescent neural stem cells transplanted in vivo can engraft into the subventricular zone 
and re-engage in neurogenesis 
If the in vitro generated p-qNSCs are a physiologically relevant culture model, then following orthotopic 
transplantation we might anticipate engraftment in vivo into the niche and reconstitution of neurogenesis. 
Previously, transplantation of acutely isolated, or primary cultured neurospheres, have focused on their 
differentiation capacity (e.g., by transplanting into the cortex or striatum). However, Neumeister et al., did 
demonstrate that short term cultured neurospheres can indeed engraft into the niche and self-renew40. This 
may be related to the tropism of transplanted NSCs to the niche in slice cultures or when injected into the 
SVZ22,40, something we have also observed in whole brain slice cultures29. We therefore reasoned that 
upon transplantation in vivo in live animals in regions adjacent to the SVZ, d-qNSCs and p-qNSCs may 
home to the niche and re-engage in their differentiation programs. 
 
We transplanted orthotopically ~2000 cells that had been cultured for 3 days in EGF/FGF, BMP/FGF or 
BMP alone into the adult SVZ region of syngeneic C57/BL6 mice (Figure 3a). Transplanted NSCs were 
stably transfected with an eGFP-expression cassette enabling tracking of their progeny. After one month, 
the SVZ and olfactory bulbs were dissected characterized using an anti-GFP antibody. We quantified 
number of GFP cells per section in each condition of transplant and in the SVZ we found 87%±12, 35%±8, 
55%±13 in EGF/FGF, BMP and BMP/FGF respectively. In the OB the number of GFP cells per section 
was 36%±7, 14%±3.6, 21%±3.2 (n=3 animals per condition, 3 brain slices per animal in the injection point). 
GFP-positive cells were clearly identifiable and engrafted successfully within the SVZ (Figure 3b) and many 
of these remained proliferative (%GFAP/Ki6737±4.3, 24±5.5 and 26.3±6, treated previously in EG/FGF, 
BMP and FGF/BMP, respectively) (Figure 3c). GFP+ cells were detected along the rostral migratory stream 
(RMS) (Supplementary 3a). GFP+ neuronal-like cells were also found within the OB that expressed beta-
III Tubulin (Figure 3d) and interneuron marker GAD65/67 (Figure 3e). p-qNSCs can therefore recommence 
neurogenesis following transplantation. 
 
The efficiency of engraftment was clearly reduced for the d-qNSCs compared to p-qNSCs and only a small 
number of neuronal cells were identified in the OB (Figure 3d). p-qNSCs therefore appear more primed for 
re-engraftment and neuronal production. Proliferative NSCs grown in (EGF/FGF) were also able to engraft 
into the niche and re-enter neurogenesis, confirming the interconvertibility of quiescence and proliferative 
states (Figure 3b and 3d). These in vivo potency assays support our hypothesis that BMP/FGF cultured 
NSCs are physiological relevant models and can therefore be used to dissect pathways regulating entry 
and exit from quiescence. 
 
 
Increased levels of Lrig1 and an interferon response signature distinguish dormant and primed 
quiescent neural stem cells 
The striking functional differences seen between d-qNSC and p-qNSC in transplantation encouraged us to 
perform a more extensive characterization of transcriptional and signaling pathways that differ between 
these two cell states. Reverse phase protein array (RPPA) were used to assess 62 proteins and 
phosphoproteins of major signaling pathways and suggested that p-qNSCs express higher levels of cell 
cycle markers relative to BMP alone, such as CYCLIN D1 and its phosphorylated target RB-P (Ser780), 
and increased levels of MYC (Figure 4a). They also display slightly higher levels of cMYC and EGFR 
(ErbB-1). This is consistent with the Fucci2a reporter experiments described above and further indicates 
these are in a state primed for cell cycle re-entry and EGFR responsiveness. 
 
We next performed RNA-seq to identify transcriptional differences associated with d-qNSCs versus p-
qNSCs. Initial PCA analysis and clustering confirmed that each cell state could be clearly distinguished 
(Supplementary 4a). Unexpectedly, however, the only gene ontology terms enriched in the p-qNSCs were 
those related to immune regulation; specifically, interferon signaling (Figure 4b). Indeed, the top 40 most 
significantly differentially expressed genes, included established immune regulators (Oasl2, Mx2, Bst2, 
Lgals9 and Rsad2) (Supplementary 4b). We noted that many of these genes are part of a previously 
reporter interferon-related damage response signature (IRDS)58, including: Bst2, Ifi44, Ifit1, Ifit3, Irf7, Mx2, 
Oals2, Usp18 (Supplementary 4b). We note that interferon response signatures were identified in single 
cell analysis of injured SVZ27, but the functional significance of this remains unclear. 
 
In addition to this signature, there were many other notable genes that were differentially expressed 
between d- and q-NSCs. Most notably, the transmembrane protein LRIG1, which interacts with ErbB family 
and reduces signaling strength by negatively regulating both protein levels and activity23, showed higher 
levels in p-qNSCs compared to d-qNSCs. LRIG1 is also known to be a quiescence regulator in other tissues 
such as the intestine and skin221,58. A very recent publication has described the expression of Lrig1 in the 
SVZ 38, but has not been functionally explored in the regulation of qNSCs, despite EGFR signaling being 
critical to their self-renewal. We therefore focused our attention in exploring whether LRIG1 is a critical 
functional regulator that explains the distinct dormant and primed quiescent NSCs and is involved in exit 
from quiescence into proliferation. 
  
We confirmed that Lrig1 mRNA levels are increased within p-qNSCs compared to d-qNSCs (Figure 4d). 
Flow cytometry confirmed that LRIG1 protein was also increased (Figure 4e) and western blotting 
confirmed higher levels of the protein within the BMP/FGF condition (Figure 4f). Reduced levels of EGFR 
Tyr1068 phosphorylation was noted in this condition, indicating reduced EGFR activation/signaling (Figure 
4f). Also, d-qNSCs (treated with BMP4) can upregulate LRIG1 when exposed to FGF, consistent with them 
shifting into the p-qNSC state (adding BMP4/FGF2) (Supplementary 4c). LRIG1 expressing cells also co-
expressed high levels of Cdt1-mCherry, CD9 and SOX2 (Supplementary 4d) indicating that Lrig1 
expression correlates with the colony forming quiescent subpopulation we had defined earlier. We 
conclude that LRIG1 is a candidate functional regulator of the transition from dormancy into a state primed 
for EGFR responsiveness and cell cycle re-entry. 
 
 
FGF-stimulated MAPK signaling controls Lrig1 expression 
The increased levels of Lrig1 detected in BMP/FGF versus BMP alone, prompted us to explore signaling 
responsiveness in each condition, and determine potential downstream signaling pathways that might 
explain their different potency. To determine which signaling pathways sustain LRIG1 levels we used 
different pharmacological inhibitors of kinases associated with candidate signaling pathways (Wortmanin, 
PI3K; GSK690693, AKT; PD0325901, MEK1/2; Tofacitinib, JAK/STAT. Inhibitors of MEK1/2 (PD0325901), 
and JAK1/2 (Tofacitinib), were each able to reduce LRIG1 protein levels and these are upstream of the 
ERK1/2 signaling and JAK/STAT signaling respectively (Figure 4g). Interplay between these pathways 
may be therefore mediate FGF-induced increases in LRIG1; however, we note that pAKT levels are 
increased in BMP/FGF (Supplementary 4e). 
 
We also determined the signaling flux after return to EGF/FGF-2 by monitoring the downstream effectors, 
phospho-ERK1/2 (Thr Thr202/Tyr204) (mitogen-activated protein kinase superfamily) and phospho-
SMAD1 (Ser463/465) (an effector of BMP signaling). We found that the duration of ERK1/2 phosphorylation 
(i.e. MAPK signaling output) is significantly extended in BMP/FGF. By contrast, activation of p-SMAD1 had 
similar levels and kinetics in each condition indicating levels of BMP signaling are not altered (Figure 4h). 
These data indicate that it is the ability to rapidly initiate and sustain MAPK signaling that likely facilitates 
cell cycle re-entry in p-qNSCs compared to d-qNSCs. 
 
LRIG1 regulates the entry and exit from quiescence in NSCs in vitro  
To explore if Lrig1 has a functional role in p-qNSCs we generated Lrig1 mutant NSCs using 
CRISPR/Cas956 (Figure 5a). PCR genotyping confirmed CRISPR/Cas9 gRNAs were active in our NSCs 
and successful mutation of Lrig1 (Figure 5b). A LRIG1 antibody was used to isolate LRIG1-negative cells 
by FACS (Figure 5c). Loss of LRIG1 protein was confirmed by immunocytochemistry in these sorted 
populations (Figure 5d). We tested the differentiation capacity in these cells and found similar multipotency 
potential to the parental control NSCs (Supplementary 5b). 
 
Using Lrig1 mutant NSCs we next asked whether there was an impact on the ability to enter or exit 
quiescence. In either BMP-4 or BMP/FGF, Lrig1 mutant cells proliferate more than parental controls (Figure 
5e and Supplementary 5c), suggesting they are not able exit cell cycle. After re-exposure EGF/FGF-2, the 
cells were able to form more significantly more colonies than their controls (Figure 5g). Restoration of 
LRIG1 in mutant NSCs (Mouse Lrig1 FLAG-tagged, expressed from CMV promoter) rescued the ability to 
enter quiescence in both BMP and BMP/FGF2 treatments (Figure Supplementary 5a). Further analysis of 
the EGFR levels and signaling activity revealed that Lrig1 mutant cells treated with BMP or BMP/FGF retain 
active EGFR signaling (EGFR Y1068), suggesting that loss of LRIG1 limits the ability to suppress autocrine 
EGFR activation in NSCs (Figure 5h). Following Gefitinib treatment (an EGFR inhibitor), the Lrig1 mutant 
cells ceased proliferation (Figure 5i/j/k; and Supplementary 5c and 5d). LRIG1 therefore seems to control 
entry to quiescence by proliferating through EGFR. 
 
To demonstrate in vivo function, we next tested the potency of Lrig1 mutant cells following transplantation 
into the adult SVZ. One month after transplantation Lrig1 mutant cells were identified successfully 
engrafted into the SVZ to a similar extent as parental controls in each condition (Figure supplementary 6a) 
(BMP, BMP/FGF or EGF/FGF). We quantified the % of GFP cells per section in each condition of transplant 
and in the SVZ we found in the Lrig1 KO transplants 83±15, 60±9, 76±5 (EGF/FGF, BMP4, BMP/FGF 
respectively) vs 79±10, 37±9, 53±11 (EGF/FGF, BMP4, BMP/FGF respectively) in the Lrig1 WT ones. 
However, in each condition there was an increased proliferation in the Lrig1 mutant cells (Figure 
Supplementary 6b). Cells lacking Lrig1 therefore cannot respond appropriately to signals within the SVZ 
niche. We conclude that Lrig1 is an important functional regulator that constrains proliferation and EGF 
signaling in p-qNSCs. 
 
Lrig1 overexpression in NSCs induces cell cycle exit 
To investigate the role of increased levels of LRIG1 in the regulation of adult NSCs, WT NSCs were 
transfected with mLrig1-FLAG, and exposed to each growth factor condition to analyze proliferative 
responses. NSCs were plated in reduced concentrations of mitogens (as these are normally saturating in 
standard culture media; we used: 10, 1, 0.1 ng/ml of EGF and FGF2) and after 48 hours of transfection 
and a pulse of 2 hours of EdU was given to the cells.  FLAG-positive and FLAG-negative cells both 
displayed low levels of GFAP (Figure 6a). Some FLAG+ cells were able to incorporate EdU (16% and 10%) 
in higher doses of mitogens (10 and 1 ng/ml EGF and FGF); however, there was significant reduction to 
0.3% EdU positive cells in 0.1ng/ml EGF and FGF conditions. By contrast, Flag negative cells maintained 
similar levels of EdU incorporation at all mitogen concentrations (Figure 6a and Figure 6b). Moreover, CD9 
was expressed in FLAG+ cells that didn’t incorporate EdU (Figure 6c), suggesting that CD9 is expressed 
in cells that are not cycling. The increase in LRIG1 levels was not associated with increased apoptosis 
(Figure 6d and Figure 6f). After 96 hours following transfection the % of FLAG+ cells with respect to the 
total population (DAPI) was reduced from that at 48hrs, consistent with the Lrig1 overexpressing cells have 
slower proliferation and being outcompeted (Figure 6d and Figure 6e). These data indicate increased 
LRIG1 can suppress EGF driven proliferation of NSCs. 
 
Disruption of Lrig1 results in activation on NSCs in vivo 
 
To functionally evaluate LRIG1 in the adult SVZ, we genetically ablated Lrig1 in vivo. Expression of Notch 
downstream effector Hes5 has been found to be expressed in quiescence NSCs28,17. In addition, we found 
that Hes5 was highly expressed in quiescence conditions in vitro (Figure 2e). We therefore targeted the 
Lrig1 gRNAs for conditional expression in Hes5 expressing cells. We performed in vivo electroporation in 
postnatal mice and analysed them after 2 months. We used tomato floxed P2 reporter mice and 
electroporated a plasmid into the ventricle (pHes5-Cas9wt-T2A-iCRE-Lrig1guide and control without guide) 
(Figure 7a). To track LRC (labelled retained cells) we injected the mice with EdU and after 3 weeks we 
sacrificed the mice. After 2 weeks of transfection, we found HES5 tomato positive cells were mostly GFAP 
positive and some ependymal cells and no DCX is co-located (Figure Supplementary 7a). In adult SVZ, 
we analysed the number of HES5 tomato positive relative to the total number of cells. There were increased 
numbers of HES5 tomato in the transfected mice with pHes5-Cas9wt-T2A-iCRE-Lrig1guide compared to 
controls (Figure 7b and 7c). We found that disruption of Lrig1 and their control in the Hes5+ population 
exhibited similar proportions of GFAP (Figure 7b and 7f). We therefore determined whether this increase 
in the number of HES5 tomato+ cells was the result of B cell activation. We analysed LRC+ cells in the 
HES5+ population and we found that NSCs within the Lrig1 disrupted SVZ displayed more LRC+HES5+ 
cells than their controls (Figure 7c and 7g). Moreover, the SVZ displayed regions of hyperplasia, and the 





In this study, we have used the tractable NSC culture models to explore the signalling events, molecular 
markers and regulatory mechanisms associated with transition of quiescent NSCs into their active and 
proliferative states. Previous single-cell profiling of mRNAs and lineage tracing have suggested a series of 
transitory states, but it has been difficult to determine those key functional pathways that regulate this 
process. The in vitro models we developed here have helped to explore these distinct quiescent states and 
identify LRIG1 as an important regulator of the primed quiescent NSC state.  Using our modified in vitro 
culture conditions (low density BMP versus BMP/FGF) we identified two distinct quiescent NSC states: 
BMP signaling in the absence of exogenous FGF induces a deep, or dormant, quiescent state; however, 
when BMP and FGF are combined, a distinct primed quiescent state emerges that can readily re-enter cell 
cycle.  
 
Previously it has been assumed the increased GFAP expression and loss of NESTIN expression that 
accompanies BMP treatment of NSCs marks their terminal differentiation to astrocytes10. However, this 
view is inconsistent with our past observations that the BMP treated cells with some low efficiency can 
revert back into a rapidly proliferating state (Pollard lab, unpublished observations). Our findings in this 
study, that many stemness markers are retained, suggests BMP signals do no drive terminal astrocyte 
differentiation, but rather impose a dormant quiescent NSC state, akin to the primed quiescent SVZ (type 
B cells) that have been reported in vivo.  
 
BMPs have been implicated as regulators of quiescence state in a variety of different adult stem cells 
including: brain, hair follicle, intestinal, hematopoietic stem cells33,22,24. Quiescence is induced by autocrine 
production of bone morphogenetic proteins (BMPs) in the hippocampus33. BMP antagonist Noggin can 
also induce dormant cells to re-enter the cell cycle, upon which they reacquire neurogenic 
potential21. Also, Fibroblast growth factor 2 (FGF2) is required to suppress terminal astrocytic 
differentiation and maintain stem cell potency during quiescence state and cooperates with BMP 
signalling54 . 
 
By exposing proliferative NSCs to BMP in combination with FGF we identified a primed G0 state that is 
primed for cell cycle re-entry. Initially, we considered that these BMP and BMP/FGF states maybe only 
subtly distinct in their transcriptional programs; however, transcriptional profiling and marker analysis 
revealed these can be considered a quite distinct and stable cell state. This is most clear from expression 
of the interferon damage response signature. The significance of the IRDS expression signature57, in 
quiescent NSCs remains unclear. However, it is interesting that recent studies have identified a role for 
interferon in the induction of quiescence in the ageing brain21. It is also notable that Lloren-Bobadilla et al., 
noted a similar induction of an interferon gamma associated pathway during injury responses27 . Our 
findings suggest that this may not be through canonical IFN ligand driven responses, but rather is a 
consequence of combined BMP and FGF signalling. It will be interesting to explore the role and significance 
of this set of these interferon target genes, and we would speculate they may have some ancestral role in 
activation of stem cells, stress responses or cell cycle re-entry checkpoint controls. It is possible these 
gene targets are activated alongside Lrig1 via JAK-mediated signals. The NSC state we have generated 
in vitro may therefore represent a distinct subset of NSCs that operate during regeneration or repair. 
 
Using the Fucci2a cells we also noted clear differences between the dormant and primed quiescent cells.  
Recent studies in Drosophila melanogaster have suggested that quiescent neural progenitors can arrest 
at G244. However, we did not identify Venus positive cells within either BMP or BMP/FGF. The key 
consequence of FGF signaling in the presence of BMP is therefore to be in a primed G0 state, defined by 
lower P27 expression. Additional in vivo studies with the Fucci reporter mice will be needed to understand 
how Cdt1 protein degradation and DNA replication licensing machinery is regulated in the dormant and 
activated quiescent states. 
 
Recent fate-mapping studies of the adult mouse SVZ seem to suggest that NSCs can transit back and 
forth between these proliferative and quiescent states3 and are consistent with our present findings. Our in 
vivo transplantation data suggests long term engraftment and re-entry into their original developmental 
program is possible, even after long term in vitro expansion. The p-qNSCs, therefore retain a capacity to 
re-engage with their previous niche and reveal their differentiation potential. This has practical importance, 
as NSC lines are highly amenable to genome editing and engineering. Thus, it now becomes feasible to 
engineering sophisticated modification in vitro and subsequent transplantation to create chimeric mice with 
transgenic or engineered NSCs. The adult SVZ NSCs may therefore be experimentally manipulated in 
similar ways to ES cells and HSCs (i.e. captured ex vivo, experimentally manipulated, and then 
transplanted to a host animal). 
 
LRIG1 was originally identified as a regulator of stem cell balance in other niches (skin and intestine). We 
noted that Codega et al., reported in their supplementary datasets that Lrig1 mRNAs are enriched in 
quiescent NSCs based on single expression profiling9 and very recent publication showed Lrig1 expression 
throughout all the lateral wall38.  Consistent with those observations, we have found that LRIG1 is 
expressed for a subset of NSCs in vivo and is highly expressed in primed quiescence NSCs in vitro. 
CRISPR-mediated ablation of Lrig1 in NSCs resulted in hyperproliferation and mutant NSCs fail to enter in 
quiescence. In vivo, transplanted mutant cells in the SVZ show similar engraftment than their control WT 
but they display higher proliferation. Elimination of LRIG1 in HES5 population resulted in enhanced 
proliferation in the SVZ. We found more numbers of GFAP/LRC+ and KI67+, suggesting that LRIG1 is 
required to maintain the quiescence state, avoiding awaking quiescence NSCs, most likely through EGFR 
signalling.  On the other hand, forced overexpression of LRIG1 in NSCs, triggered cell cycle exit.  All these 
data indicate there is an ongoing balance between LRIG1 levels and EGFR signaling that regulates 
quiescence NSCs transiting into an activated and proliferative state. The findings reported here raise many 
further questions. Do the distinct NSC states contribute equally to homeostatic neurogenesis? Do some 
cells serve as a reservoir for brain repair? Are there regional differences in quiescence control by LRIG1 
within the heterogeneous NSCs? What is the significance of the interferon response signature in the 
activation in vivo?  How long can this primed state persist in vivo?  
 
Our findings are also likely to be relevant to brain cancer, glioblastoma (GBM). GBMs are driven by cells 
with NSC characteristics, including both quiescent and proliferative compartments. Quiescent GBM stem 
cells, evade cytotoxic and anti-mitotic therapies, are through to underlie the re-growth of the tumour. It is 
noteworthy that genome-wide association studies have been identified a risk allele associated with LRIG1 
(rs11706832)32. We would speculate that the quiescent cells in GBM are maintained in a primed state, with 
high Lrig1 expression and is consistent with their elevated CD9 expression42 and high IRDS expression 
that is associated with tumour resistance therapy34, and our findings of a lack of strong cytostatic responses 
induced by BMP7.  
 
In summary, we conclude that BMP cooperates with FGF signaling to prepare cells for cell cycle re-entry 
– forcing them into a primed quiescent state. These primed NSCs are non-cycling, but upregulate critical 
markers and pathways in preparation for the exit from quiescence. We identify an important functional role 
for LRIG1 in NSCs, as it allows levels of EGFR to be highly expressed, but limits the signaling activity, 
thereby priming cells in a primed G0 for rapid cell cycle re-entry. LRIG1 is therefore a gatekeeper for the 
exit from quiescence. As LRIG1 is a well-known quiescence regulator of stem cells in intestinal and skin 
stem cells that constrains receptor-tyrosine kinase signaling pathways20,59, this primed quiescent state may 




Cell culture  
NSCs were isolated from the young adult 6-8 weeks old SVZ and maintained in vitro in serum-free basal 
medium supplemented with N2 and B27 (Life Technologies), Laminin-1 (Sigma, 1 μg/ml) and growth 
factors EGF and FGF2 (Peprotech, 10 ng/ml each)5. All the experiments were done in early passage after 
passage 3. For colony-forming assay NSCs were plated at low density (1000 cells per well-6 multiwell 
plate). We scored the total of number of colonies per well.  A minimal number of 6 grouped cells were 
considered a colony. Treatments with BMP-4 and FGF2/ BMP-4 were for 3 days. BMP-4 (10ng/ml, 
Peprotech, AF-120-05ET-100), FGF2 (10 ng/ml, Peprotech, # 100-18b, EGF (10ng/ml, Peprotech, #315-
09), Gefitinib (LKT laboratories, G1721). Differentiation induction, NSCs were plated in no clonal density 
with 10ng/ml, FGF for 2 div and then 2% FCS for 5 div. 
 
Animals 
Mice used in this study were young adults (6-8 weeks old). Mice of the Fucci2A strains were generously 
provided by Richard Mort (IGMM) and Bl6 strains were maintained at the core facility of the University of 
Edinburgh in accordance with UK regulations. For NSCs transplants, animals were anaesthetized with 
100% w/w Inhalation vapour, liquid isofluorane. Animals were fixed in a stereotactic apparatus stereotactic 
apparatus Stoelting (SKU S51725) and an automatic injector KD Scientific product, Model KDS-311-CE, 
catalogue number 78-9311UU. NSCs concentrated (∼1 × 106/ul) were injected in a volume of 0.2ul with a 
Hamilton syringe (0.1 μl min!") for 2 min. Stereotactic coordinates used were 0 Anterior, 0.7mm Lateral, 
2.5mm Deep. For in vivo detection of slow proliferating cells we used EdU (invitrogen) is dissolved in PBS 
at 5mg/ml. We inject (IP) 1 mg/20 g mouse, 200 ul once daily for 3 days. After 3 weeks, mice were sacrificed 
and EdU detected by Click it kit.  All animal procedures were performed under UK Government Home 
Office approved Procedure Project License (PC0395462) and following approval of the local Animal 
Welfare and Ethical Review Body (AWERB). 
  
Electroporation in vivo 
Plasmids were injected into the ventricle of isoflurane-immobilized Rosa26-tdTomatofl/fl pups at 
postnatal day 2 using an Eppendorf femtojet, followed by electroporation (5 square pulses, 50 
msec/pulse at 100 V, with 850 msec intervals). DNA was prepared to a final concentration of 1ug/ul 
with 0.1% fast green prepared in saline (0.9% NaCl)54. Plasmids used for electroporation in vivo were 
Hes5-SpCas9wt-T2A-iCRE-Lrig1guideRNA or Hes5-SpCas9wt-T2A-iCRE-controlRNA. Sequence of 




Animals were deeply anaesthetized and transcardially perfused with 4% paraformaldehyde in 0.1 M PBS 
and brains processed for vibratome sectioning (Leica VT1,000S vibratome Samples were blocked in 10% 
normal goat serum and 0.2% Triton X-100 in PBS for 1 h and incubated for 48 h in blocking buffer with the 
appropriate primary antibodies: GFP (1: 500, 13970 Abcam) , BIII tubulin (1:200 Covance, MMS435P), 
GFAP (1:100, G3893, Sigma-Aldrich), GFAP (1:500, Z0334 DAKO) KI67 (1:100 Thermo RM9106), OLIG2 
(1:200, AB9610, Millipore), SOX2 (1:100, AB5603, Millipore), NESTIN (1:10, Rat 401, Developmental 
Studies Hybridoma Bank), ID1 (1;100, Biocheck, bch 1/37-2), LRIG1 (1:100, R&D, AF3688), S100B (1:100, 
Dako Z0311, 1:100), CD9 (1:100, 14-0091-82, eBioscience, 1:500), O4  (1:100, R&D MAB1326), p27 
(1:200, sc-1641, Santa Cruz) , PCNA (1:200, sc-56, Santa Cruz), RFP (1:500, Abcam 62341), FLAG M2 
(1:1000, Sigma F1804). 
 
Cells were fixed with 4% paraformaldehyde for 20 min, incubated in blocking buffer (10% normal goat 
serum and 0.2% Triton X-100 in 0.1M phosphate buffer saline) for 30 min, and incubated overnight at 4°C 
with the indicated primary antibodies. After several washes with PBS,  immunoreactivity was detected 
appropriate Alexa Fluor-conjugated (Life Technologies) secondary antibody (1:500) diluted in blocking 
buffer. Cells were counterstained with 4′,6′, -diamidino-2-phenylindole (DAPI) or DRAQ5 and mounted with 
Fluorsave (Calbiochem).  
 
Manufacturer’s instructions were followed for both EdU (Click it Thermo Fisher (C10337) and for protein 
synthesis (Click it Thermo Fisher OP-Puro (C10456)) assays. Images were taken and analyzed using 
Confocal (Leica SP8, 4 and 5 detectors) and Nikon TiE. For quantification of OP-Puro each cell was 
measured using Fiji and negative control with no fluorescence was used as negative control. For 
quantification of the immunofluorescent in vivo signals in Fucci in each cell were measured with Fiji as 
mean pixel (px) density as follows: above background, 5 px; mCherry high ≥ 50 px; mCherry low = 4–50 
px; and mCherry negative ≤ 4 px. For CD9 levels quantification, we used same procedure above 




Flow cytometry and sorting 
 
For cell sorting using Antibodies, we splited the cells and washed with PBS. Pellet of cells was incubated 
with the primary antibodies LRIG1 (1:200, R&D AF3688) and CD9 (1:500, eBioscience 14-0091) diluted in 
PBS with 4%FCS in the incubator at 37C for 1 hour. After we washed with PBS to remove primary 
antibodies, secondary Alexa Fluor-conjugated (Life Technologies) antibodies diluted (1:500) in PBS-
4%FCS were incubated for 10 min.  When we sorted Fucci line, after the incubation of the antibodies we 
selected the different populations based in the levels in intensity of red mCherry (high and low). In both 
populations (high and low mCherry) we isolated more positive CD9 cells and plated for colony forming 
assay and RNA extraction. We used BD LSR Fortessa (SORP) and BD Fusion Cell Sorter for analysis and 
sorting respectively.  
 
Western Immunoblotting 
Immunoblotting was performed using standard protocols. Antibodies were diluted in 5% milk powder in 
PBS Triton 0.1%, and protein detection was carried out with HRP-coupled secondary antibodies and X-ray 
films. The following primary antibodies were used: LRIG1 (1:100, R&D, AF3688), EGFR (1:1000, D38B1, 
Cell Signaling, #4267), EGFR-p (1:1000, Tyr 1068, Cell Signaling, #3777), pSMAD1-5 (1:1000, Cell 
Signaling, #9516), SMAD1 (1:1000, Cell Signaling, #9743) , ppERK1/2 (1:1000, Cell Signaling #9101), 
ERK1/2 (1:1000, Cell Signaling 4695), Phospho-AKT (Ser473) (1:1000, Cell Signaling #9271), AKT 
(1:2000, CST #9272),  SOX2 (1:1000, Abcam #92494), GAPDH (1:50000; GenTex, GTX627408).  β-
ACTIN (1:5000, Sigma #A5316). No accutase was used for splitting the cells from the plate. 
 
Transfection and derivation of clonal lines 
For generation of eGFPp27-mCherryPCNA NSC line, guide RNA was manually designed to introduce the 
eGFP tag into the 5′ UTR of PCNA or mCherry tag into the 3’ UTR of CDKN2A (p27) based on the 
annotation of the 5’UTR, initial coding exon, final coding exon, and the 3′ UTR sequence. A ∼100 bp 
sequence around the stop codon was used as an input for guide RNA design using the DESKGEN cloud 
design tool. High-scoring guide RNAs were chosen based on minimal predicted off-target cleavage events 
and having a cut site within the 5’ UTR (PCNA) or 3′ UTR (CDKN2A/p27). For dsDNA block design, the 
eGFP/mCherry tag sequence was flanked by ∼200 bp homology arms and a PAM blocking mutation 
(NGG>NGC) was introduced to prevent re-cutting of donor DNA by Cas9. Ribonucleoprotein (RNP) were 
assembled and transfected12. Synthetic Alt-R crRNA and tracrRNA were manufactured by Integrated DNA 
Technologies. dsDNA block oligonucleotides was manufactured by Twist Bioscience and recombinant 
Cas9 protein was made in-house. Sequence of the guide RNA for p27, ACGTTTGACATCTTCCTCCT and 
for PCNA, GCGTGCCTCAAACATGGTGG. NSCs were transfected using PiggyBac-GFP-Luc BSD 
plasmid. For Lrig1 mutant cells, design and construction of CRISPR sgRNAs are described in Bressan et 
al. 2017. We disrupted Exon1 based in Suzuki et al. We used 4D Amaxa nucleofector and DN-100 program. 
For Lrig1 deletion we used 2 RNA guides with the following sequences: AAGGCGACTCTCAGCGCGGC 
and TACTCACAGGCTGCGCGTCC. To overexpress Lrig1 we used mLrig1-CFLAG (Mouse LRIG1 
expressed from CMV promoter; gift from Prof Kim Jensen, University of Copenhagen). See table 1 primer 
sequences. 
 
PCR-based Lrig1 genotyping cells 
 
For genomic DNA isolation, each well of a confluent 24-well plate was lysed with 40 µl of lysis buffer (0.45% 
NP40, 0.45% Tween20, 1x NEB LongAmp PCR buffer) containing 0.2 mg ml−1 proteinase K (Sigma). After 
a 2 hour digestion at 55 °C, samples were heated to 95 °C (10 min) and 1–2 µl of the lysate was used in a 
10 µl PCR reaction. PCR mix consisted of 0.2 µl DMSO (100% v/v, Sigma), 0.3 µl dNTPs (10 mM, Thermo 
Fisher Scientific), 2.0 µl 5x LongAMP buffer (NEB), 0.4 µl LongAMP Taq DNA polymerase (NEB), and 12 
pmol of each primer. Thermal cycling was performed using the following conditions: 1 cycle 94 °C for 3 
min; 35 cycles (94 °C for 30 s, 60 °C for 30 s, 65 °C for 2 min); followed by final extension at 65 °C for 10 
min. Amplicon around 1200bp. (See table 1 primers sequences). 
 
Quantitative real-time RT-PCR 
 
RNA was extracted using the RNeasy spin column kit (Qiagen), plus DNase treatment to eliminate gDNA. 
cDNA was generated with SuperScript III (Invitrogen), and quantitative RT-PCR was performed using 
Taqman Universal PCR Master Mix (Applied Biosystems). The following Taqman assays (Life 
Technologies) were used: Egfr (Mm00433023_m1, Hes5 (Mm00439311_g1), Tlx (Mm00455855_m1), 
mcm2 (Mm00484815_m1), Sox2 (Mm03053810_s1), Prom1 (Mm00726334_s1), Bmi1 
(Mm03053308_g1), FoxG1 (Mm02059886_s1), Gfap (Mm99999915_g1), p21 (Mm04205640_g1), Nfix 
(Mm00477791_m1), Pdgfra (Mm00440701_m1), Ephrin2 (Mm01215897_m1), Foxo3 
(Mm00490673_m1),  Id1 (Mm00775963_g1),  Sox9 (Mm0083422_m1,)  Gli3 (Mm0049654_m1), Gli1 
(Mm00492345_m1), Fabp7 (Mm00445225_m1), Lrig1 (Mm00456116_m1), S100 (Mm0048597), Aqp4 
(Mm00802131). 
 
RNA-seq processing and analysis 
RNA extraction was performed using the Qiagen RNeasy Plus minispin column kit, eluting in 50 µL of 
RNase-free water, and using an additional DNase step. RNA concentration was determined using the Qubit 
RNA High-Sensitivity kit (Life Technologies). Sample concentration and quality was assessed using the 
Aligent Tapestation and Nanodrop, only samples with a RIN value of 9.6 or above were used. For RNA-
seq we used RNA-Seq Quantification Library (Low input Library) BGISEQ-500RS. Fastq files were trimmed 
via Trimgalore (version 0.5.0) and aligned with Kallisto (version 0.44.0) to the mm10 transcriptome (Martin, 
2011; Bray et al., 2016). Tximport (version 1.8.0) was used to summarise read counts before subsequent 
normalisation and differential expression as per DESeq2 (version 1.27.32). All downstream analysis and 
visualisation were completed following regularised logarithm transformation (rlog) via DESeq2. GO 
enrichment analysis was completed via the hypergeometric test using the R package clusterprofiler 
(version 3.15.4) on differentially expressed genes ( > 1.5 log2 fold change, < 0.05 FDR) (Yu et al., 2012).  
 
RPPA analysis 
For RPPA we prepared the samples Lysis Buffer: 1% Triton X-100, 50mM HEPES, pH 7.4, 150mM NaCl, 
1.5mM MgCl2, 1mM EGTA, 100mM NaF, 10mM Na pyrophosphate, 1mM Na3VO4, 10% glycerol, 
containing freshly added protease and phosphatase inhibitors from Roche Applied Science Cat. #: 
05056489001 and 04906837001, respectively. 4x SDS Sample Buffer: 40% Glycerol, 8% SDS, 0.25M Tris-
HCL, pH 6.8. Before use, we added 2-mercaptoethanol at 1/10 of the volume.  Clarified supernatants in 
biological triplicate were adjusted to 2 mg/mL concentration and printed onto nitrocellulose-coated slides 
(Grace Bio-Labs) in a dilution series (four serial 2-fold dilutions) in technical triplicate using an Aushon 
2470 arrayer (Aushon Biosystems). Slides were blocked, probed with validated primary antibodies and 
detected with DyLight 800-conjugated secondary antibodies (New England BioLabs). Slides were read 
using an InnoScan 710-IR scanner (Innopsys) and quantified using Mapix (Innopsys). Relative 
fluorescence intensities were normalised to respective FastGreen-stained spots (total protein), and data 




Results are presented as mean ± SEM of a number (n) of independent experiments. Statistical significance 
was determined by two-tailed Student’s t-tests using GraphPad (version 9.0.0). Treatment experiments 
were analyzed by paired t-test. When comparisons were performed with relative values (normalized values 
and percentages), data were normalized by using an arc-sen transformation. Values of P < 0.05 were 




The datasets generated during and/or analysed during the current study are available from the 
corresponding author on reasonable request and will be deposited the GEO database (GSE168189). The 
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Figures and Figure Legends 
 
Figure 1 | Quiescence NSCs express high levels of the Cdt1 red Fucci reporter in vivo. 
(a) Immunohistochemistry for GFAP (green) in the SVZ. mCHERRY Fucci reporter (red) and nuclear counterstaining 
with DAPI (blue). Right, detail of GFAP positive cells expressing different levels of Fucci red reporter and quantification 
(n=3 independent mice). (b) Immunohistochemistry for GFAP (yellow), CD9 (green), mCHERRY Fucci reporter (red) 
and nuclear counterstaining DAPI (blue). Right, detail of GFAP positive cells with different levels of CD9 and 
mCHERRY Fucci reporter. Nuclear counterstaining with DAPI (blue).  (c)  Live imaging of the Fucci NSCs treated with 
EGF/FGF, BMP and BMP/FGF showing mCHERRY (red) and VENUS (green) reporters. (d) Flow cytometry Fucci 
quantification of the percentage of cells positive for Cdt1-mCHERRY (red) and VENUS (green), negative or low levels 
of fluorescence (pale pink) and double positives for both reporters (yellow) (n=3). (e) qPCR for different markers (Egfr, 
Hes5, Mmc2, Sox2, Gfap, Id1) in the different conditions (data relative to EGF/FGF) (n=3). (f) Immunocytochemistry 
for CD9 (yellow) in Fucci NSC line, mCHERRY (red) and nuclear counterstaining with DAPI (blue) (n=3 independent 
NSC lines). (g) Quantification of the CD9 mean intensity in NSCs treated for EGF/FGF2, BMP4 and BMP/FGF2 for 3 
days. Quantification by Fiji. (n=3 independent experiments per condition, average intensity of min 500 cells per group).  
(h) Number of colonies in the sorted population of Fucci cell cycle reporter based high levels of CD9 and mCHERRY 
levels. (h-high, l-low) (n=3). Data are shown as mean ± SEM of the indicated number of the experiments (n) (*p < 0.05; 
**p < 0.01; ***p < 0.001). St :striatum, LV: Lateral Ventricle. Scale bar in (a) and (b) is 20 um, (c) and (f) is 50 um. Scale 
in details:10 um. Source data are provided as a Source Data File. 
 
 
Figure 2 | BMP and FGF2 condition drives a quiescence reversible state in NSCs. (a) Histogram of cytometry 
quantification of CD9 in the different conditions MFI (median fluorescence intensity) (n=4). (b) Immunostaining of NSCs 
treated with EGF/FGF, BMP and BMP/FGF for 3 days. OLIG2 (red), SOX2 (green), GFAP (green) NESTIN (green) 
KI67 (red) and ID1 (red). Nuclear counterstaining in blue with DRAQ5.  Images showing ICC in group of cells to 
appreciate staining (n=5). (c) Quantification of the DNA content using DAPI and flow cytometry (n=3). (d) Cytometry 
analysis of double knock-in mCherry-p27 and eGFP-PCNA NSC line in the different conditions (n=4).  (e) Quantification 
of the relative expression of different genes in the cells treated with BMP and BMP/FGF2 (n=3). (f) EdU incorporation 
images (yellow) in the NSCs in presence of EGF/FGF. Nuclear counterstaining with DAPI (blue). Quantification of 
percentage of EdU positive cells, during the treatment (left), and after to re-exposure to mitogens (right) (n=3). (g) (top) 
Phase contrast images of the colony forming assay of the cells treated with BMP and BMP/FGF. (bottom). 
Quantification of the number of colonies after to re-exposure to mitogens (n=5). Scale bar in (b), (f), (g) is 50 um. Mean 
is indicated in the box and whiskers plots from minimum to maximum. Data are shown as mean ± SEM of the indicated 







Figure 3 | Quiescence NSCs allow long term regeneration. (a) Schematics of the experiments. NSCs derived from 
mouse, after several months of expansion in vitro are transplanted in the SVZ for 1 month. (b) Panoramic pictures of 
the NSCs (GFP, green) in the SVZ after 1 month. NSCs were treated with EGF/FGF, BMP-4 and FGF/BMP-4 
previously to be transplanted. (c) Immunostaining for GFP (green), GFAP (yellow), Ki67 (red) nuclear counterstaining 
with DAPI (blue). (d) Immunostaining for GFP (green), BIII TUBULIN (red), DAPI (blue) showing  neurons arriving to 
the OB. (e) Immunostaining for GFP (green), BIII tubulin (magenta) and GAD65/67 (red) and nuclear counterstaining 
with DAPI (blue). LV: Lateral Ventricle. OB: Olfactory Bulb. Detail of co-staining GFP and BIII TUBULIN (red). Scale 
bar in (b) is 100 um, (c), (d) is 50 um and in (e) is 20 um. Scale bar in detail is 20 um (n=3 analyzed transplanted mice 





Figure 4 | Dormant and primed quiescent NSCs have distinct signaling pathways and transcriptional 
programs. (a) RPPA data analysis of the NSCs in BMP and BMP/FGF (n=3). (b) The top biological GO terms in 
biological process enriched genes in BMP/FGF condition. (c) Heatmap showing the top significant genes. (d) Lrig1 
expression by QPCR in the different conditions (n=3). (e) Histogram of LRIG1 expression by cytometry (n=3). 
Quantifications show mean fluorescent intensity (MFI). (f) Immunoblot of LRIG1, EGFR (total) and EGFR-P. Loading 
control GAPDH. (g) Immunoblot for LRIG1, pAKT, ppERK1/2, GAPDH in NSCs treated with BMP and BMP+FGF for 
3 days (n=3). Different kinases inhibitors were used (Wortmannin, GSK, PD0325901, Tofacitinib) (n=3). (h) Immunoblot 
for SOX2, pSMAD1, SMAD1, GAPDH, ppERK1/2, ERK in NSCs treated with BMP and BMP/FGF for 3 days and re-
exposure to EGF+FGF, different time exposures (n=3).  (i) Immunoblot for Lrig1 in NSCs treated with BMP/FGF and 
BMP and re-exposure to EGF/FGF in a time course. Loading control, ERK1/2 (n=3). Data are shown as mean ± SEM 





Figure 5 | LRIG1 is necessary to enter in quiescence state.  
(a) Schematics of Lrig1 gene disruption. (b) PCR confirming CRISPR-Cas9 (control and parental line). (c) Flow 
cytometry plots with the transfected NSCs. (d) ICC for LRIG1(red) and nuclear counterstaining with DAPI (blue) in 
sorted populations after transfection. (e) EdU quantification of the WT and Lrig1 KO NSCs in the different conditions 
(EGF/FGF2, BMP and BMP/FGF2) (n=3). (f) Quantification of the single cell colony formation in the WT and Lrig1 KO 
cells in EGF/FGF2 (n=3). (g) Quantification of the number of colonies of deficient and WT NSCs after the treatment 
with BMP and BMP/FGF2, after to re-exposure to mitogens (n=3). (h) Lrig1 KO cells maintain high levels of pEGFR; 
WB of EGFR total and EGFR-p in WT and Lrig1 KO cells in the different conditions (EGF/FGF2, BMP and BMP/FGF2). 
Loading control GAPDH. (i) Quantification of the EdU positive cells in KO and control cells in the different conditions 
using Gefitinib (n=3 per condition). (j) Single cell colony forming assay of the deficient and control NSCs using Gefitinib 
(n=3 per genotype and condition, 48 single cells plated in each group each time).  (k) Quantification of the colony 
formation of the WT and Lrig1 KO NSCs in each condition (BMP and BMP/FGF2) using EGFR inhibitor (Gefitinib) (n=3 
per condition). Scale bar in d=50um. Data are shown as mean ± SEM of the indicated number of the experiments (n) 







Figure 6 | Lrig1 overexpression in NSCs induces cell cycle exit. (a) IHC for FLAG (green), and GFAP (red). 
Detection of  EdU (magenta) and nuclear counterstaining in blue (DAPI) with NSC overexpressing Lrig1 in different 
concentrations of mitogens (10, 1 and 0.1 ng/ml of both EGF/FGF). (b) Quantification of EdU positive cells after 2 
hours of pulse in the FLAG+ and FLAG- populations. (c) IHC for CD9 (red) and FLAG (green). Detection of EdU in 
magenta and nuclear counterstaining with DAPI (blue). (d) IHC of FLAG (green), active CASPASE-3 (red).  Detection 
of EdU (magenta) and nuclear counterstaining with DAPI (blue). Cells analyzed 48 and 96 hours after transfection. (e) 
Quantification of EdU positive cells in the FLAG+ and FLAG- population after 48h and 96 hours of transfection. (f) 
Quantification of active CASPASE-3 after 48h and 96h of transfection in FLAG+ and FLAG- populations (n=3 
independent transfections, minimal number of 500 cells per condition). Scale bar in (a) is 50 um, (c) is 10 um and (d) 
is 30 um. Data are shown as mean ± SEM of the indicated number of the experiments (n). Source data are provided 
as Source Data File. 
 
 
Figure 7 | LRIG1 control proliferation in the SVZ. (a) Schematics of the in vivo electroporation procedure. (b) IHC 
for GFAP (green), Hes5 tomato (red) and DAPI counterstain in mice electroporated with Control plasmid and Lrig1 
guide. (c) IHC for LRC (light blue), GFAP (green) and HES5 tomato (red). Nuclear counterstaining with DAPI (blue). 
(d) IHC for KI67 (green), HES5 TOMATO (red) and nuclear counterstaining with DAPI (blue). (e) Quantification of the 
number of HES5 tomato positive cells relative to the total ones (DAPI). (f) Quantification of the number of GFAP positive 
cells in the Hes5 TOMATO population. (g) Quantification of the LRC+ in GFAP/HES5 TOMATO population (h) 
Quantification of the percentage of KI67 positive cells in HES5 TOMATO population. (i) Graphical schematics of the 
results. Scale bar in b, c and d is 10 um.  LV: Lateral Ventricle, ST: Striatum. BV: Blood Vessel. (N=4 mice per 
condition). Mean is indicated in the box and whiskers plots from minimum to maximum. Data are shown as mean ± 
SEM of the indicated number of the experiments (n). (∗p < 0.05; ∗∗p < 0.01).  Schematics in (a) are done using 
BioRender software (original photo of the SVZ ).  Source data are provided as Source Data File. 
 
 
 
 
